Compare YTRA & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YTRA | MDXH |
|---|---|---|
| Founded | 2005 | 2003 |
| Country | India | Belgium |
| Employees | N/A | N/A |
| Industry | Transportation Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.3M | 68.7M |
| IPO Year | 2011 | 2021 |
| Metric | YTRA | MDXH |
|---|---|---|
| Price | $0.89 | $0.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $1.80 |
| AVG Volume (30 Days) | 29.4K | ★ 207.3K |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.55 | $5.40 |
| Revenue Next Year | N/A | $12.92 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.72 | $0.40 |
| 52 Week High | $2.00 | $5.33 |
| Indicator | YTRA | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 35.19 | 47.98 |
| Support Level | $0.83 | $0.51 |
| Resistance Level | $0.96 | $0.75 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 5.91 | 43.26 |
Yatra Online Inc is an Indian consumer travel platform provider and online travel agent. The company is organized into the following business segments; Air Ticketing which derives maximum revenue, Hotels and Packages, and Other Services. It mainly provides travel-related services, which include domestic and international air ticketing, hotel bookings, homestays, holiday packages, bus ticketing, rail ticketing, activities and ancillary services. It also involves hosting advertisements on its internet websites, the sale of rail and bus tickets, and facilitating website access to travel insurance companies. Some of its applications include Yatra Mini, Yatra Web Check-In, Yatra Corporate, and Travelguru HomeStay.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.